InMed Pharmaceuticals Strengthens Patent Portfolio with Three New U.S. Patents

InMed Pharmaceuticals (NASDAQ: INM), a leader in the manufacturing, development, and commercialization of rare cannabinoids and proprietary small molecule drug candidates, has announced the receipt of three patents granted in the U.S. This development significantly strengthens its patent portfolio, which now totals 13 patent families as of August 20, 2024. The newly issued patents cover a formulation and method of use for treating epidermolysis bullosa and related connective tissue disorders, biosynthesis manufacturing processes, and an ocular drug delivery formulation.

Eric A. Adams, InMed's President and CEO, expressed satisfaction with the patent issuances, highlighting their role in increasing the commercial value of the company's programs and ensuring long-term protection for its drug research and development efforts. The patents are pivotal for safeguarding novel drug candidates, manufacturing methods, formulations, and their applications in developing treatments for diseases with significant unmet medical needs.

The expansion of InMed's patent portfolio is a testament to its innovative approach in the pharmaceutical industry, particularly in the realm of cannabinoid-based therapies. This advancement not only positions InMed as a frontrunner in the field but also opens new avenues for addressing complex medical conditions through rare cannabinoids and small molecule drug candidates. The implications of these patents extend beyond the company, promising potential breakthroughs in treatment options for patients worldwide.